The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
Open accessAbstract
BACKGROUND.: Temozolomide is an active agent in metastatic pancreatic endocrine carcinomas. In vitro data indicate that the combination of capecitabine and temozolomide is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. The authors retrospectively evaluated the efficacy of capecitabine and temozolomide in 30 patients with metastatic pancreatic endocrine carcinomas to assess response rate, progression free survival (PFS), and overall survival (OS). METHODS.: Patients with metastatic, well, or moderately differentiated pancreatic endocrine carcinomas who had not received prior systemic chemotherapy were treated with capecitabine (750 mg/m 2 twice daily, days 1‐14) and temozolomide (200 mg/m 2 once daily, days 10‐14) every 28 days. RESULTS.: Among 30 patients treated, 21 (70%) patients achieved an objective radiographic response. Median progression‐free survival was 18 months. The rate of survival at two years was 92%. Only 4 patients (12%) experienced grade 3 or 4 adverse events. CONCLUSIONS.: The combination of capecitabine and temozolomide is associated with an exceptionally high and durable response rate in metastatic endocrine carcinomas of the pancreas. Clinical endpoints, including response rate, survival, and toxicity, are superior to those observed with streptozocin‐based regimens Cancer 2011. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cited by
Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors
Kunz, P. L., Reidy-Lagunes, D., Anthony, L. B., Bertino, E. M., Brendtro, K., Chan, J. A., Chen, H., Jensen, R. T., Kim, M. K., Klimstra, D. S., et al. (2013) · Pancreas · doi:10.1097/mpa.0b013e31828e34a4 · Cited by 580
Self-citation177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Das, S., Al-Toubah, T., El-Haddad, G., & Strosberg, J. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1685381 · Cited by 135
Self-citationWell-differentiated pancreatic neuroendocrine tumors: from genetics to therapy
de Wilde, R. F., Edil, B. H., Hruban, R. H., & Maitra, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.9 · Cited by 122
Approach to the Patient: Insulinoma
Hofland, J., Refardt, J. C., Feelders, R. A., Christ, E., & de Herder, W. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad641 · Cited by 91
Metadata
- Authors
- Strosberg, J. R., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J., & Kvols, L.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-09-07
- Volume
- 117
- Issue
- 2
- Pages
- 268-275
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2090232354
- Cited by
- 766
- References
- 1
- FWCI
- 35.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. https://app.cochat.ai/papers/10.1002/cncr.25425
- The paper
- Strosberg, J. R., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J., & Kvols, L. (2011). First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. https://doi.org/10.1002/cncr.25425
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
